DCTH Stock Overview
An interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Delcath Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.76 |
| 52 Week High | US$12.88 |
| 52 Week Low | US$2.60 |
| Beta | 0.76 |
| 11 Month Change | -8.61% |
| 3 Month Change | 7.02% |
| 1 Year Change | 226.42% |
| 33 Year Change | 0.21% |
| 5 Year Change | -65.06% |
| Change since IPO | -100.00% |
Recent News & Updates
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Nov 18Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Nov 01
Recent updates
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Nov 18Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Nov 01Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Sep 10Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Aug 27Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 07Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
Jan 15Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?
Oct 04Delcath Systems Q2 2022 Earnings Preview
Aug 05Delcath Systems to raise $5M in stock and warrants offering
Jul 18Delcath Systems: Revisiting A $5 Lottery Ticket
May 17Shareholder Returns
| DCTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.9% | 1.5% | 2.2% |
| 1Y | 226.4% | 20.8% | 31.6% |
Return vs Industry: DCTH exceeded the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: DCTH exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| DCTH volatility | |
|---|---|
| DCTH Average Weekly Movement | 9.3% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DCTH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DCTH's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 76 | Gerard Michel | www.delcath.com |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
Delcath Systems, Inc. Fundamentals Summary
| DCTH fundamental statistics | |
|---|---|
| Market cap | US$312.06m |
| Earnings (TTM) | -US$34.12m |
| Revenue (TTM) | US$22.64m |
13.8x
P/S Ratio-9.1x
P/E RatioIs DCTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCTH income statement (TTM) | |
|---|---|
| Revenue | US$22.64m |
| Cost of Revenue | US$4.23m |
| Gross Profit | US$18.41m |
| Other Expenses | US$52.54m |
| Earnings | -US$34.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 81.31% |
| Net Profit Margin | -150.70% |
| Debt/Equity Ratio | 23.3% |
How did DCTH perform over the long term?
See historical performance and comparison